Skip to main content
SpringerLink
Log in

Hepatic Encephalopathy After TIPS Placement: Predictive Factors, Prevention Strategies, and Management

  • Review
  • TIPS
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Hepatic encephalopathy (HE) is a challenging complication after transjugular intrahepatic portosystemic shunt (TIPS) placement. Despite recent advances, much is still uncertain regarding risk factors, preventative measures, and the management of HE after TIPS placement. Appropriate patient selection and pre-procedural risk stratification remain areas of focus. In this manuscript, we discuss the current state of research related to HE after TIPS placement, including information regarding risk stratification, complication prevention, and treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rowley MW, Choi M, Chen S, Hirsch K, Seetharam AB. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt: risk factors and outcomes with revision. Cardiovasc Intervent Radiol. 2018;41(11):1765–72. https://doi.org/10.1007/s00270-018-1992-2.

    Article  PubMed  Google Scholar 

  2. Vizzutti F, Schepis F, Arena U, et al. Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. Intern Emerg Med. 2020;15(1):37–48. https://doi.org/10.1007/s11739-019-02252-8.

    Article  PubMed  Google Scholar 

  3. Suhocki PV, Lungren MP, Kapoor B, Kim CY. Transjugular intrahepatic portosystemic shunt complications: prevention and management. Semin Intervent Radiol. 2015;32(2):123–32. https://doi.org/10.1055/s-0035-1549376.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Mamiya Y, Kanazawa H, Kimura Y, Narahara Y, Yamate Y, Nakatsuka K, Sakamoto C. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res. 2004;30(3):162–8. https://doi.org/10.1016/j.hepres.2004.09.003.

    Article  PubMed  Google Scholar 

  5. Yanny B, Winters A, Boutros S, Saab S. Hepatic encephalopathy challenges, burden, and diagnostic and therapeutic approach. Clin Liver Dis. 2019;23(4):607–23. https://doi.org/10.1016/j.cld.2019.07.001.

    Article  PubMed  Google Scholar 

  6. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2010;51(3):1062–9. https://doi.org/10.1002/hep.23367.

    Article  CAS  PubMed  Google Scholar 

  7. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7(9):515–25. https://doi.org/10.1038/nrgastro.2010.116.

    Article  PubMed  Google Scholar 

  8. RiChard J, Thornburg B. New techniques and devices in transjugular intrahepatic portosystemic shunt placement. Semin Interv Radiol. 2018;35(3):206–14. https://doi.org/10.1055/s-0038-1660800.

    Article  Google Scholar 

  9. Rössle M, Euringer W. Hepatic encephalopathy in patients with transjugular intrahepatic portosystemic shunt (TIPS). In: Mullen KD, Prakash RK, editors. Hepatic Encephalopathy. Humana Press; 2012. p. 211–20.

    Chapter  Google Scholar 

  10. Lin X, Gao F, Wu X, Cai W, Chen X, Huang Z. Efficacy of albumin–bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol. 2021;33(6):862–71. https://doi.org/10.1097/MEG.0000000000001801.

    Article  CAS  PubMed  Google Scholar 

  11. Coronado WM, Ju C, Bullen J, Kapoor B. Predictors of occurrence and risk of hepatic encephalopathy after TIPS creation: a 15-year experience. Cardiovasc Intervent Radiol. 2020;43(8):1156–64. https://doi.org/10.1007/s00270-020-02512-7.

    Article  PubMed  Google Scholar 

  12. Yin X, Zhang F, Guo H, et al. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in Cirrhotic Patients. Sci Rep. 2020;10(1):9381. https://doi.org/10.1038/s41598-020-65227-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yang Y, Fu S, Cao B, et al. Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study. Hepatol Int. 2021;15(3):730–40. https://doi.org/10.1007/s12072-021-10188-5.

    Article  PubMed  Google Scholar 

  14. Casadaban LC, Parvinian A, Minocha J, et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci. 2015;60(4):1059–66. https://doi.org/10.1007/s10620-014-3391-0.

    Article  PubMed  Google Scholar 

  15. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16(5):531–5. https://doi.org/10.1046/j.1440-1746.2001.02487.x.

    Article  CAS  PubMed  Google Scholar 

  16. Nardelli S, Gioia S, Pasquale C, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2016;111(4):523–8. https://doi.org/10.1038/ajg.2016.29.

    Article  PubMed  Google Scholar 

  17. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42(5):674–9. https://doi.org/10.1016/j.jhep.2004.12.028.

    Article  CAS  PubMed  Google Scholar 

  18. Bai M, Qi X, Yang Z, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26(6):943–51. https://doi.org/10.1111/j.1440-1746.2011.06663.x.

    Article  PubMed  Google Scholar 

  19. Nardelli S, Lattanzi B, Merli M, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. Hepatology. 2019;70(5):1704–13. https://doi.org/10.1002/hep.30692.

    Article  PubMed  Google Scholar 

  20. Wijarnpreecha K, Werlang M, Panjawatanan P, et al. Association between sarcopenia and hepatic encephalopathy: a systematic review and meta-analysis. Ann Hepatol. 2020;19(3):245–50. https://doi.org/10.1016/j.aohep.2019.06.007.

    Article  CAS  PubMed  Google Scholar 

  21. Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15(6):934–6. https://doi.org/10.1016/j.cgh.2016.10.028.

    Article  PubMed  Google Scholar 

  22. Farkas ZC, Rashid T, Chen YS, et al. The correlation between sarcopaenia and post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy: a single-institution review. Arch Med Sci Atheroscler Dis. 2019;4:e89-93. https://doi.org/10.5114/amsad.2019.85380.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114(6):1296–303. https://doi.org/10.1016/s0016-5085(98)70436-6.

    Article  CAS  PubMed  Google Scholar 

  24. Chung H-H, Razavi MK, Sze DY, et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications? J Gastroenterol Hepatol. 2008;23(1):95–101. https://doi.org/10.1111/j.1440-1746.2006.04697.x.

    Article  CAS  PubMed  Google Scholar 

  25. Yao J, Zuo L, An G, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal hypertension. J Gastrointestin Liver Dis. 2015;24(3):301–7.

    Article  PubMed  Google Scholar 

  26. Lewis DS, Lee T-H, Konanur M, et al. Proton pump inhibitor use is associated with an increased frequency of new or worsening hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2019;30(2):163–9. https://doi.org/10.1016/j.jvir.2018.10.015.

    Article  PubMed  Google Scholar 

  27. Pillai AK, Andring B, Patel A, Trimmer C, Kalva SP. Portal hypertension: a review of portosystemic collateral pathways and endovascular interventions. Clin Radiol. 2015;70(10):1047–59. https://doi.org/10.1016/j.crad.2015.06.077.

    Article  CAS  PubMed  Google Scholar 

  28. Borentain P, Soussan J, Resseguier N, et al. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement. Diagn Interv Imaging. 2016;97(6):643–50. https://doi.org/10.1016/j.diii.2016.02.004.

    Article  CAS  PubMed  Google Scholar 

  29. He C, Lv Y, Wang Z, et al. Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis. Dig Liver Dis. 2018;50(12):1315–23. https://doi.org/10.1016/j.dld.2018.05.022.

    Article  PubMed  Google Scholar 

  30. Praktiknjo M, Simon-Talero M, Romer J, et al. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J Hepatol. 2020;72(6):1140–50. https://doi.org/10.1016/j.jhep.2019.12.021.

    Article  PubMed  Google Scholar 

  31. Bian J, Wang A, Lin J, et al. Association between proton pump inhibitors and hepatic encephalopathy: a meta-analysis. Medicine (Baltimore). 2017;96(17):e6723. https://doi.org/10.1097/MD.0000000000006723.

    Article  CAS  Google Scholar 

  32. Dai R, Sag AA, Martin JG, et al. Proton pump inhibitor use is associated with increased rates of post TIPS hepatic encephalopathy: replication in an independent patient cohort. Clin Imaging. 2021;77:187–92. https://doi.org/10.1016/j.clinimag.2021.04.034.

    Article  PubMed  Google Scholar 

  33. Wang Q, Lv Y, Bai M, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67(3):508–16. https://doi.org/10.1016/j.jhep.2017.05.006.

    Article  PubMed  Google Scholar 

  34. Luo X, Wang X, Zhu Y, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm. Cardiovasc Intervent Radiol. 2019;42(5):737–43. https://doi.org/10.1007/s00270-019-02162-4.

    Article  PubMed  Google Scholar 

  35. Miraglia R, Maruzzelli L, Tuzzolino F, Petridis I, D’Amico M, Luca A. Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm PTFE-covered stents. Radiology. 2017;284(1):281–8. https://doi.org/10.1148/radiol.2017161644.

    Article  PubMed  Google Scholar 

  36. Trebicka J, Bastgen D, Byrtus J, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival. Clin Gastroenterol Hepatol. 2019;17(13):2793-9.e1. https://doi.org/10.1016/j.cgh.2019.03.042.

    Article  PubMed  Google Scholar 

  37. Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007;27(6):742–7. https://doi.org/10.1111/j.1478-3231.2007.01522.x.

    Article  CAS  PubMed  Google Scholar 

  38. Perarnau JM, Le Gouge A, Nicolas C, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol. 2014;60(5):962–8. https://doi.org/10.1016/j.jhep.2014.01.015.

    Article  PubMed  Google Scholar 

  39. Pieper CC, Sprinkart AM, Nadal J, et al. Postinterventional passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stents. J Vasc Interv Radiol. 2015;26(3):388–94. https://doi.org/10.1016/j.jvir.2014.10.021.

    Article  PubMed  Google Scholar 

  40. Schepis F, Vizzutti F, Garcia-Tsao G, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;16(7):1153-62.e7. https://doi.org/10.1016/j.cgh.2018.01.029.

    Article  PubMed  Google Scholar 

  41. Miraglia R, Maruzzelli L, Di Piazza A, et al. Transjugular intrahepatic portosystemic shunt using the new gore viatorr controlled expansion endoprosthesis: prospective, single-center Preliminary Experience. Cardiovasc Intervent Radiol. 2019;42(1):78–86. https://doi.org/10.1007/s00270-018-2040-y.

    Article  PubMed  Google Scholar 

  42. Kloster M-L, Ren A, Shah KY, et al. High incidence of hepatic encephalopathy after viatorr controlled expansion transjugular intrahepatic portosystemic shunt creation. Dig Dis Sci. 2020. https://doi.org/10.1007/s10620-020-06716-2.

    Article  PubMed  Google Scholar 

  43. Praktiknjo M, Abu-Omar J, Chang J, et al. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep. 2021;3(3):100264. https://doi.org/10.1016/j.jhepr.2021.100264.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Shi Y, Tian X, Hu J, et al. Efficacy of transjugular intrahepatic portosystemic shunt with adjunctive embolotherapy with cyanoacrylate for esophageal variceal bleeding. Dig Dis Sci. 2014;59(9):2325–32. https://doi.org/10.1007/s10620-014-3150-2.

    Article  CAS  PubMed  Google Scholar 

  45. Simon-Talero M, Roccarina D, Martinez J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018;154(6):1694-1705.e4. https://doi.org/10.1053/j.gastro.2018.01.028.

    Article  PubMed  Google Scholar 

  46. Luo S-H, Chu J-G, Huang H, Zhao G-R, Yao K-C. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy. World J Gastroenterol. 2019;25(9):1088–99. https://doi.org/10.3748/wjg.v25.i9.1088.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Chen L, Xiao T, Chen W, et al. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial. Liver Int. 2009;29(7):1101–9. https://doi.org/10.1111/j.1478-3231.2009.02016.x.

    Article  PubMed  Google Scholar 

  48. American Association for the Study of Liver Diseases. European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61(3):642–59. https://doi.org/10.1016/j.jhep.2014.05.042.

    Article  Google Scholar 

  49. Bureau C, Thabut D, Jezequel C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021;174(5):633–40. https://doi.org/10.7326/M20-0202.

    Article  PubMed  Google Scholar 

  50. de Wit K, Schaapman JJ, Nevens F, et al. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol. 2020;7(1):e000531. https://doi.org/10.1136/bmjgast-2020-000531.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother. 2015;49(2):207–19. https://doi.org/10.1177/1060028014559244.

    Article  CAS  PubMed  Google Scholar 

  52. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006. https://doi.org/10.1002/14651858.CD002094.pub3.

    Article  PubMed  Google Scholar 

  53. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458–63. https://doi.org/10.1038/ajg.2013.219.

    Article  CAS  PubMed  Google Scholar 

  54. Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology. 2013;58(1):325–36. https://doi.org/10.1002/hep.26370.

    Article  CAS  PubMed  Google Scholar 

  55. Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD001939.pub4.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66(6):1727–38. https://doi.org/10.1002/hep.29306.

    Article  CAS  PubMed  Google Scholar 

  57. Jiang Q, Jiang X-H, Zheng M-H, Chen Y-P. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol. 2009;24(1):9–14. https://doi.org/10.1111/j.1440-1746.2008.05582.x.

    Article  CAS  PubMed  Google Scholar 

  58. Sidhu SS, Sharma BC, Goyal O, Kishore H, Kaur N. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018;67(2):700–10. https://doi.org/10.1002/hep.29410.

    Article  CAS  PubMed  Google Scholar 

  59. Taylor AG, Kolli KP, Kerlan RK Jr. Techniques for transjugular intrahepatic portosystemic shunt reduction and occlusion. Tech Vasc Interv Radiol. 2016;19(1):74–81. https://doi.org/10.1053/j.tvir.2016.01.008.

    Article  PubMed  Google Scholar 

  60. De Keyzer B, Nevens F, Laenen A, et al. Percutaneous shunt reduction for the management of TIPS-induced acute liver decompensation: a follow-up study. Ann Hepatol. 2016;15(6):911–7. https://doi.org/10.5604/16652681.1222110.

    Article  PubMed  Google Scholar 

  61. Schultheiss M, Bettinger D, Boettler T, Thimme R, Rossle M. Severe hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS): value of shunt reduction and occlusion. JSM Hepat. 2017;2(1):1009.

    Google Scholar 

  62. Joseph AS, Sandhu B, Khalil A, Lopera J. Transjugular portosystemic shunt reductions: a retrospective single-center experience. J Vasc Interv Radiol. 2019;30(6):876–84. https://doi.org/10.1016/j.jvir.2019.01.031.

    Article  PubMed  Google Scholar 

  63. Mukund A, Chalamarla LK, Singla N, Shasthry SM, Sarin SK. Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration. Eur Radiol. 2020;30(6):3462–72. https://doi.org/10.1007/s00330-019-06644-4.

    Article  PubMed  Google Scholar 

  64. Privitera G, Figorilli F, Jalan R, Mehta G. Portosystemic shunt embolization and recurrent ascites: a single-center case series. Gastroenterology. 2018;155(5):1649–50. https://doi.org/10.1053/j.gastro.2018.06.092.

    Article  PubMed  Google Scholar 

  65. Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57(6):2448–57. https://doi.org/10.1002/hep.26314.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank Kerry Hawkins and Megan Griffiths for the administrative and organizational support for the manuscript.

Funding

This study was not supported by any funding.

Author information

Authors and Affiliations

  1. Department of Radiology, Hospital of The University of Pennsylvania, Philadelphia, PA, USA

    Xin Li

  2. Section of Interventional Radiology, Imaging Institute, Cleveland Clinic Main Campus, Cleveland, OH, USA

    Sasan Partovi, Sameer Gadani, Charles Martin, Dustin Thompson, Abraham Levitin & Baljendra Kapoor

  3. Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA

    Wendy Melissa Coronado

Authors
  1. Xin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sasan Partovi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy Melissa Coronado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sameer Gadani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dustin Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Abraham Levitin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Baljendra Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sasan Partovi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants performed by any of the authors.

Informed Consent

For this type of study informed consent is not required.

Consent for Publication

For this type of study consent for publication is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Partovi, S., Coronado, W.M. et al. Hepatic Encephalopathy After TIPS Placement: Predictive Factors, Prevention Strategies, and Management. Cardiovasc Intervent Radiol 45, 570–577 (2022). https://doi.org/10.1007/s00270-021-03045-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-021-03045-3

Keywords

Search

Navigation